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Background: Aberrant microRNA (miRNA) expression plays an essential role in the pathogenesis of Hepatocellular
Carcinoma (HCC). However, specific involvement of miRNAs in HCC remains incompletely understood. The aim of
this study was to explore the relevant microRNAs involved in the development of HCC.
Methods: MicroRNA microarray was used to screen for the differentially expressed miRNAs in cancerous tissue and
adjacent non-cancerous control tissue from patients with HCC (n = 3). Quantitative PCR was subsequently used to
verify the results of microarray. Based on the findings, we investigated the role of miR-492 in the pathogenesis of
HCC in vitro and in vivo using three tumor cells lines. Furthermore, we analyzed the clinical correlation of miR-492
expression with patient survival (n = 28).
Results: We showed that microRNA-492 (miR-492) was elevated in HCC samples from patients with hepatic cancer.
Knockdown of miR-492 attenuated the proliferation of cancer cell lines in vitro and inhibited primary tumor growth
in vivo in SCID mice. We identified PTEN as a functional target for miR-492. Overexpression of miR-492 resulted in
decreased PTEN expression and was associated with increased AKT activation in cancer cell lines. Moreover,
miR-492-mediated increase of the proliferation of cancer cells was able to be suppressed by a PI3K inhibitor
and an AKT inhibitor. The HCC patients with high miR-492/low PTEN had poorer survival.
Conclusions: miR-492 is implicated in the regulation of HCC progression through PTEN and AKT pathway. The
data suggest that miR-492 is a biomarker of HCC and a potential therapeutic target for hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers and the leading causes of cancer-associated
death. Chronic inflammation and cirrhosis as a result of
viral hepatitis B and C, fatty liver and alcohol abuse are
usually considered the culprits of HCC which usually has a
very poor prognosis. Clinically only a very limited number
of patients are eligible for potentially curative treatment
options such as surgical resection followed by orthotopic
liver transplantation. Therefore, there is an urgent need to
develop effective therapeutic approaches for the large
number of HCC patients with advanced disease. For a long
time, hepatocarcinogenesis has been considered to be the
result of different genetic alterations that ultimately lead to* Correspondence: suncy24@163.com
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unless otherwise stated.malignant transformation. Nowadays, cancer development
is no longer thought to be induced only by genetic and
genomic alterations, but also should be considered as a re-
sult of epigenetic alterations.
MicroRNAs (miRNAs), an abundant class of endogen-
ous, small, noncoding RNAs of ∼ 22 nucleotides in length,
are post-transcriptional regulators that bind to specific
cognate sequences in the 3′-untranslated region (3′-UTR)
of target transcripts, usually resulting in translational re-
pression and gene silencing. They are expressed in a
tissue-specific manner and play an important role in cell
proliferation, apoptosis, and differentiation. It has been
shown that miRNAs play crucial roles in the regulation of
diverse biological processes, such as development, inflam-
mation, and tumorigenesis [1]. It has become evident that
the expression level of miRs globally altered in cancer.
MiR-21 has recently been found to be closely associated
with the progression of pancreatic cancer. In vivo, miR-21td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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model of pancreatic ductal adenocarcinoma [2]. MiR-200
is a powerful marker and determining factor of the epithe-
lial phenotype of cancer cells [3]. MiR-183 is dysregulated
in breast cancer and its expression correlates with estro-
gen receptor and HER2/neu receptor expression. Induced
overexpression of miR-183 inhibited migration of breast
cancer cells [4]. It was recently found that miR-122 was
downregulated in HCC. The oncogene c-Myc repressed
miR-122 gene expression by associating with its promoter
and by down-regulating Hnf-3β expression, whereas miR-
122 indirectly inhibited c-Myc transcription by targeting
Tfdp2 and E2f1 [5]. Furthermore, it was reported that
miR-101, an important tumor-suppressive miRNA in hu-
man hepatocarcinomas, was epigenetically repressed by
PRC2 complex in a c-Myc-mediated manner [6]. There-
fore, micro RNA-mediated regulation plays a critical role
in the development of hepatocarcinomas.
In this study, we investigated the possible involvement
of microRNAs governing the expansion and functions of
hepatic cells. We compared the expression of miRs in
HCC specimens derived from patients with hepatic can-
cer and found that miR-492 is elevated in HCC. Further
in vitro and in vivo experiments were performed to dem-
onstrate the critical role of miR-492 in regulating cancer
cell growth and promotion of tumor progression. We
also investigated the mechanism which underlies the
regulation of tumor cells by miR-492 and showed that
miR-492 activated the PI3K/AKT pathway through tar-
geting phosphatase and tensin homolog (PTEN). These
findings provide new insights into the molecular mecha-
nisms that regulate the expansion and functions of hep-
atic cancer cells and the exploration of potential targets
for therapeutic intervention.
Materials and methods
Cell lines, animals and patient samples
HCT116, HuH-6 and HepG2 cells were cultured in
Dulbecco’s Modified Eagle Medium supplemented with
10% fetal calf serum, L-glutamine, antibiotic and antimy-
cotic cocktail (Life Technologies, USA). The cells were in-
cubated at 37°C in a humidified atmosphere with 5% CO2.
SCID mice were purchased from Shanghai Slac animal
center (Shanghai, China). The animal protocol was ap-
proved by the institutional animal care committee of
Guiyang Medical College, China. A total of 28 human
primary liver cancer samples and their paired adjacent
non-cancerous tissue samples were obtained with in-
formed consent from patients of the Affiliated Hospital
of Guiyang Medical College, China. Clear hepatocellular
carcinoma was diagnosed histopathologically. Of these
samples, two-third of patients were with cirrhosis.
Twenty-two percent of patients were positive for HbsAg
and Seventeen percent of patients were positive foranti-hepatitis C (HCV) antibody. The tumor sizes of 8
patients were less than 2 cm while that of 13 patients
were between 2 cm and 3 cm. The tumor sizes of 7 pa-
tients were greater than 3 cm.
Microarray assay
Total RNA was isolated using Trizol reagent (Invitrogen)
and RNeasy Mini Kit (Qiagen), and the samples were
then labeled using the miRCURY Hy3/Hy5 Power label-
ing kit and hybridized on the miRCURY LNA™ Array
(v.11.0). Scanning was performed with the Axon Gene-
Pix 4000B microarray scanner. The intensity of green signal
was calculated after background subtraction, and replicated
spots on the same slide were averaged by getting a median
intensity. We used the median normalization method to
obtain “normalized data”: normalized data = (foreground-
background)/median; the median represents the 50% quan-
tile of miRNA intensity which is >50 in all samples after
background correction. Significance of results was deter-
mined via fold change and t test. The threshold value we
used to screen differentially expressed miRNAs was fold
change > =1.5 or fold change = <0.8 and p value <0.05.
Transfection of siRNA
Cells were transfected with Lipofectamine RNAiMax re-
agent (Invitrogen) according to the manufacturer’s guide-
lines. In brief, at the day 6 of culture, 5 × 105 cells were
plated in antibiotic-free culture medium and transfected
with 100 pmol/well siRNAs. After overnight incubation,
the medium was supplemented with antibiotics and the
cells were used for further experiments.
Gene expression analysis
Total RNA was isolated from cell lines with Trizol re-
agent (Invitrogen) according to manufacturer’s instruc-
tions and the RNA concentration was measured with
the ND-1000 NanoDrop spectrophotometer (Nanodrop).
miRNAs were quantified from 1 μg total RNA using the
miScript PCR System (Qiagen). U6 and 5S RNAs were
used as internal controls. cDNA samples were diluted 1
into 100 for miRNA detection or U6 and 1 into 10,000
for 5S RNA detection.
Autologous xenograft
Recombinant HIV-1-derived lentiviral vector was pro-
duced following transfection of HEK293 T cells (2 × 105)
with plasmids using per 10 cm dish: 5 ug of pLenti-
shRNA construct, 6 ug of packaging plasmids using Mega-
Tran transfection reagent with Opti-MEM16 according to
manufacturer’s instructions (Origen, China). Medium was
changed the day following transfection and collected
24 hours later to harvest the produced viral particles
which were purified by centrifugation. Lentiviral vectors
were titered by physical titers measuring P24 and reverse
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mice (5 in each group) that received an injection in the
right flank using 5 × 106 of HCT116 cell line infected with
lentiviral scramble or anti-miR-492 (day 0). Tumors were
found in all these mice and were palpable 14 d later. On
day 30, all mice were sacrificed and the tumors were iso-
lated for evaluation of the volume (volume = length ×
width2 × π/6).
Colony formation
2 × 103 resuspended cells were placed in methylcellulose
media and the vial was vigorously vortexed to thor-
oughly mix cells with the media. After approximately
20 minutes, 1.1 mL of the final cell mixture was added
to a 35 mm culture plate using a 3 mL syringe fitted
with a 16 gauge needle with gently rotating the plate to
allow the media spread evenly. Two sample plates and
an uncovered plate containing 3–4 mL sterile water
were placed in a 100 mm culture plate with cover. The
sterile water plate served to maintain the humidity ne-
cessary for colony development. The cells were incu-
bated for 5–10 days at 37°C and 5% CO2 without
disturbing the plates during the incubation period to
prevent shifting of the colonies. Individual colonies
representing cell growth were counted as previously de-
scribed [7].
3′-UTR luciferase reporter assay
The PTEN 3′-UTR luciferase reporter construct was
made by amplifying the PTEN mRNA 3′-UTR sequence
and cloning it downstream of the CMV-driven firefly lu-
ciferase cassette in the pMIR-REPORT vector (Ambion).
HEK-293 cells were co-transfected with 80 ng luciferase
reporter plasmid, 40 ng pRL-TK-Renilla-luciferase plas-
mid, and miR-492 (final concentration, 20 nM). Luciferase
activities were measured using the Dual-Luciferase Re-
porter Assay System (Promega).
MTT cell proliferation assay
Briefly, cells were seeded at 5 × 103 cells per well in a 96-
well dish and grown in 10% FCS DMEM medium. After
24 h, cells were infected with lentivirus (miR-492 or control).
The proliferation of cells was determined using MTT Cell
Proliferation Assay (Promega) according to manufacturer’s
instructions at different time points following infection.
Western blotting
Proteins were extracted from cell lines, resolved by SDS-
PAGE and transferred to PVDF membrane. After block-
ing for 1 h at room temperature, blots were incubated
overnight at 4°C with antibodies to PTEN, P-AKT, T-
AKT, β-actin (Cell Signaling Technology) diluted ac-
cording to the manufacturer’s recommendations. After
wash, secondary HRP-conjugated antibodies (dilution1:10,000; Pierce) were added and blots were incubated at
room temperature for 1 h. The protein bands were visu-
alized using ECL chemiluminescence (Pierce).
Statistical analysis
Numerical data were expressed as mean ± SD. ANOVA
and Student’s t tests were done to determine the differ-
ences in the means among the various treatment groups.
p <0.05 was considered statistically significant. The SPSS
10.0.2 software package (SPSS, Inc.) was used for ana-
lysis. The Kaplan-Meier survival curve was plotted with
Graphpad Prism 5.0 software (Graphpad Software, Inc.).
Results
miR-492 is elevated in HCC tissues from patients
By comparing the miRNA expression profile between
HCC tissues and adjacent non-cancerous tissues using
an array-based miRNA profiling, eight differentially
expressed miRNAs were identified. To select the altered
miRNAs, the cutoff criteria were set as that the ratio of
miRNA by HCC to control was greater than 1.5 folds or
less than 0.8 folds for upregulation or downregulation.
Among all selected miRNAs, we choose the most upreg-
ulated and downregulated miRNAs for further analysis.
Two were upregulated (miR-492 and miR-224) and six
were downregulated (miR-191, miR-122, miR-192, miR-
101, miR-302b, miR-148a) (Figure 1A). We confirmed
the expression of these miRNAs by qRT-PCR analysis
(Figure 1B). Consistent with the array data, the results
showed that miR-492 expression is generally the highest
and differs most significantly (tumor vs. control, p < 0.01).
Knockdown of miR-492 inhibits cancer cell proliferation
in vitro
To understand the functional relevance of miR-492 over-
expression in cancer, the expression of miR-492 was
downregulated by transfection of siRNA to miR-492 in
human cancer cell lines HCT116, HepG2, and HuH-6. As
shown in Figure 2A, knockdown of miR-492 significantly
inhibited the proliferation of these cells (p < 0.05). More-
over, colony formation of these cell lines was also signifi-
cantly inhibited by knockdown of miR-492 (Figure 2B).
Knockdown of miR-492 attenuates tumor growth in vivo
We next examined the effect of miR-492 knockdown on
tumor growth in vivo using orthotopic implantation of
HCT116 cells infected with lentiviral scramble or anti-
miR-492. After injection of equal amount cells into
SCID mice for 4 weeks, autopsy was conducted to com-
pare the tumor size. As shown in Figure 3, significantly
smaller tumors were observed in the SCID mice injected
with the HCT116 cells infected with the lentiviral anti-
miR-492 compared to that in control animals (1507 ±
817 vs. 495 ± 342 mm3).
Figure 1 Comparison of miRNA expression profile between HCC tissues and adjacent non-cancerous tissues using an array-based miRNA
profiling. (A) The heat map diagram shows the result of the differentially expressed miRNAs (only differentially expressed miRNAs with fold
change > =1.5 or fold change = <0.8 and p value <0.05 are included) from miRNA microarray. (B) The expression levels of these miRNAs were
measured by qRT-PCR and normalized to the expression of U6 in each sample. Data are the mean ± SD (n = 3) of one representative experiment.
Similar results were obtained in three independent experiments. n: adjacent non-cancerous tissues, t: HCC tissues. *refers to p < 0.05 and **refers
to p < 0.01 in a Student’s t test between the HCC group and the control group.
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It is generally accepted that miRNAs exert their func-
tion through regulating the expression of their target
genes. Thus, we took advantage of multiple prediction
algorithms (miRBase, PicTar, and TargetScan v.5.1) to
identify the potential miR-492 targets related to the
functions of tumor-associated myeloid-derived suppres-
sor cells (MDSCs). Among hundreds of potential target
genes, PTEN, a major negative regulator of the PI3K/
AKT signaling pathway involved in cell growth, apop-
tosis, motility, and differentiation, was demonstrated in
this study to be a functional target of miR-492 in HCCs.
We first compared PTEN mRNA and protein expres-
sion levels between tumor and adjacent non-tumorous
tissues. Notably, the PTEN protein level was remarkably
downregulated in tumor HCC tissues compared with
the control whereas PTEN mRNA expression showedFigure 2 Knockdown of miR-492 attenuates cencer cell proliferation an
inhibited using siRNA transfection to cancer cell lines HuH-6, HCT116 and H
using MTT. Statistical analysis was carried out on day 4 and day 5. (B) Colo
with siRNA to miR-492 and control siRNA (NC). Data are presented as meanno difference (Figure 4A). The inconsistency between
PTEN mRNA and protein levels hints that a miRNA-
mediated mechanism may be involved. The regulation
of PTEN by miR-492 ought to be investigated by the ob-
servation of the expression of PTEN protein but not the
expression of PTEN mRNA. To confirm the possibility
that PTEN may be regulated post-transcriptionally by
miR-492, 3′-UTR of PTEN reporter plasmid was con-
structed. When the reporter plasmids with miR-492
mimics or the scrambled oligonucleotide were trans-
fected into HEK-293 cells, we observed that the miR-
492 mimics markedly decreased the luciferase activity
(Figure 4B). To further confirm PTEN is a target of
miR-492, we transfected PTEN plasmid to HepG2 cells
to analyze the proliferation of HepG2 cells. The results
showed that transfection of PTEN plasmid counteracted
the effects of miR-492 by downregulating of thed colony formation in vitro. (A) The expression of miR-492 was
epG2. Subsequently, the proliferations of cancer cells were determined
ny formation of three cell lines were measured in the culture treated
± SD. *refers to p < 0.05 between the groups.
Figure 3 Anti-miR-492 inhibits the in vivo growth of HCT116 in SCID mice. (A) HCT116 cells (5 x 106) were infected with lentiviral siRNAs to
miR-492 or scramble control and subsequently transferred into SCID mice (n = 5 per group). After 30 days, tumors were isolated from mice and
their volume were calculated as “volume = length × width2 × π/6”. (B) The average tumor volume was calculated from 5 mice per group and
statistically analyzed to compare the difference between the experimental group and the control group. **refers to p < 0.01.
Figure 4 PTEN is a functional target of miR-492 in HCCs. (A) HCC tissues and the adjacent non-cancerous tissues were subject to Western blot
and real-time PCR analyses to assess PTEN mRNA and protein levels. Data are the mean ± SD (n = 4) of one representative experiment. Similar
results were obtained in at least three independent experiments. (B) HEK-293 cells were transfected with either miR-492 mimics (20 nM) or the mutant
3′-UTR of miR-492 (20 nM) along with the matched control using 80 ng of indicated vectors and 40 ng of pRL-TK. After 24 h, firefly luciferase activity
was measured and normalized by Renilla luciferase activity. Data are the mean ± SD (n = 4) of one representative experiment. Similar results were
obtained in at least three independent experiments. The proliferation of HepG2 cells transfected with miR-492 plasmid (0.5 nM) and different
concentrations of PTEN plasmid (5 nM, 10 nM, 20 nM) was determined by MTT. *indicates the significant difference between the control and
PTEN transfected cells. (C) HCT116 or HepG2 cells were infected with the indicated lentivirus for 24 h, and p-AKT, total AKT and PTEN levels
were detected by immunoblot analysis. Data shown is one representative experiment out of three. (D) miR-492 transfection enhanced the
proliferation of both HCT116 and HepG2 which was inhibited by the PI3K and ATK inhibitors.
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HepG2 cells, overexpression of miR-492 resulted in the
reduction of PTEN level, associated with increased AKT
phosphorylation, whereas knockdown of miR-492 pro-
duced opposite effects (Figure 4C). Furthermore, miR-
492-induced increases of proliferation of HCT116 and
HepG2 were markedly reversed by PI3K and AKT in-
hibitors (Figure 4D).
miR-492-PTEN is a clinically relevant pathway in HCC
We proceeded to evaluate the clinical relevance of our
experimental observation by examining the expression
of miR-492 and PTEN in tumor and paired adjacent
non-tumorous tissues from 28 HCC patients. A signifi-
cant inverse correlation (p < 0.001, r = −0.45, R2 = 0.122)
was observed between the expression of miR-492 and
PTEN in these HCC samples (Figure 5A), suggesting
PTEN as a clinically relevant miR-492 target in HCC.
Moreover, HCC patients with tumors which exhibits
more than 2-fold upregulated miR-492 and more than
1.5-fold downregulated PTEN expression compared to
the paired adjacent non-tumorous tissues were found to
be significantly associated with poorer overall survival
(p < 0.05, Figure 5B). Collectively, these data suggest that
deregulation of miR-492 expression with subsequent de-
regulation of PTEN expression may serve as a prognos-
tic biomarker predicting the patients’ survival outlook.
Discussion
Although extensive efforts have been devoted to under-
standing the molecular pathogenesis of HCC, few effect-
ive treatments currently exist. Systemic chemotherapy
and radiotherapy, two conventional cancer therapies, ex-
hibited low response rates and no demonstrated survival
benefits in HCC [8]. Treatment with Sorafenib, an ap-
proved multikinase inhibitor, resulted in only modestlyFigure 5 Upregulation of miR-492 and downregulation of PTEN express
plot represents the statistically significant correlation in the relative transcri
paired adjacent non-tumor tissues from 28 HCC patients. Each spot represe
linear regression line is marked as the solid line. (B) Kaplan-Meier survival c
miR-492 upregulation (more than 2 fold) and PTEN downregulation (more
Upregulation of miR-492 and downregulation of PTEN expression is significprolonged survival [9]. Development of novel therapeu-
tics for the prevention and treatment of HCC is there-
fore urgently needed. Despite the general lack of activity
of conventional therapeutics in HCC, hepatocytes have
been shown to readily take up antisense oligonucleotides
[10], raising the hope that small nucleic acid-based mol-
ecules may have utility against HCC. MicroRNAs (miR-
NAs) are small, endogenous RNAs that regulate gene
expression through messenger RNA (mRNA) degrad-
ation or inhibition of translation [11]. Aberrant miRNA
expression plays an essential role in HCC pathogenesis,
and miRNA replacement or inhibition therapies have
been suggested as potential therapeutics for HCC [12].
As proof of principle, recombinant adeno-associated
virus (AAV)-mediated overexpression of miR-26a was
recently shown to attenuate primary MYC-driven tumor
formation in a transgenic (Tg) mouse model [13]. Des-
pite the safety concerns on using adenovirus, the devel-
opment of new therapies based on miRNA manipulation
is a current research focus and believed to be the next
generation of therapy for various cancers.
Not only deregulated gene expression but also the al-
teration of post-transcriptional gene silencing mediated
by microRNA were demonstrated to influence pathogen-
esis of human cancers by either acting as tumor sup-
pressor or as oncogene [14]. MiRNAs originated from
introns of protein and nonprotein coding genes or even
rarely from exons [15]. Of note, distinct miRNA signa-
tures have already been used for the classification and
prognosis of various cancers, including HCC [16-18].
Previous studies showed both consistent and inconsist-
ent results regarding the correlation between miR-492
and the development of gastrointestinal cancers. It was
reported that miR-492 could originate from the coding
sequence of the hepatoblastoma marker gene keratin 19
(KRT19) and miR-492 along with its associated targetsion is associated with poorer survival of HCC patients. (A) Scatter
pt expression of miR-492 and PTEN (p < 0.001) in the tumor versus
nts data from one HCC patient presented in the Log2 scale and the
urve for HCC patients classified based on whether HCC tumor showed
than 1.5 fold), compared to the paired adjacent non-tumor samples.
antly associated with poorer patient survival (p <0.05).
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ical utility and could assist to explore targeted therapies,
especially in metastatic hepatoblastoma with a poor
prognosis [19]. However, there was an inconsistent re-
port describing that the gene polymorphisms of miR-
27a, miR-146a, miR-196a-2, miR-492, miR-492a and
miR-608 were not associated with the presence of colon
cancer in European subjects [20]. It should be noted the
upregulation of miR-492 was not limited to a specific
type of liver cancer as it was also considered a biomarker
for hepatoblastoma besides HCC. In addition to miR-
492, other miRs such as miR-494 and miR-449 were also
reported to be associated with various cancers [21-23].
miR-145 potently suppressed growth of three different
colon carcinoma cell line [24]. However, the exact func-
tional role of miRNAs in the development, progression
as well as its regulatory pathway remains unclear. Our
findings suggested a novel miR-492-PTEN pathway im-
plicated in the progression of HCC. It is conceivable that
PTEN is not exclusively regulated by a specific miRNA;
other miRNAs such as miR-494 likely regulates PTEN
too. This brings up the question whether the increase of
miR-492 is relevant to a particular cancer stage. In our
study, the expressions of other miRNAs such as miR-
224, miR-148a has been found to either increase or de-
crease in HCC. The role of those miRNAs in the patho-
genesis of HCC might be worth exploration.
Given that PTEN acts as a major negative regulator of
the PI3K/AKT signaling pathway, the repression of
PTEN by miR-492 might play an important role in pro-
liferation of other types of cell too. It was reported that
the activity of MDSC was regulated by miR-494 through
PTEN/AKT. The downregulation of PTEN by miR-494
enhanced the activity of AKT and its downstream path-
ways, promoted the accumulation of MDSCs in tumor
tissues [23]. Thus, tissue specific regulation of PI3K/
AKT pathway should also be addressed in this regard. In
conclusion, this study described the upregulation of
miR-492 in cancerous tissue of hepatocellular carcinoma
and depicted a new miR-492-PTEN-AKT pathway in the
progression of hepatocellular carcinoma. It also showed
that miR-492 upregulation/PTEN downregulation corre-
lated with the survival outlook of patients with HCC.
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